A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
← catalyst calendarNCT07575932 · readout in 350 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
872estimated
Sites
65
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-11 | actual | When the study began enrolling |
| Primary completion | 2027-08-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
- Overweight and/or Obesity
- Overweight or Obesity
- Overnutrition
- Nutrition Disorders
- Nutritional and Metabolic Diseases
- Body Weight
Interventions
- Drug: PF-08653945
- Drug: PF-08653944
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in body weight
measured Baseline (Week 0) to Week 48
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed